Aix Marseille Univ, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France.
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Methods Mol Biol. 2023;2618:133-145. doi: 10.1007/978-1-0716-2938-3_10.
Dendritic cells (DCs) represent one of the most important immune cell subsets in preventing the host from pathogen invasion by promoting both innate and adaptive immunity. Most research on human dendritic cells has focused on the easy-to-obtain dendritic cells derived in vitro from monocytes (MoDCs). However, many questions remain unanswered regarding the role of different dendritic cell types. The investigation of their roles in human immunity is hampered by their rarity and fragility, which especially holds true for type 1 conventional dendritic cells (cDC1s) and for plasmacytoid dendritic cells (pDCs). In vitro differentiation from hematopoietic progenitors emerged as a common way to produce different DC types, but the efficiency and reproducibility of these protocols needed to be improved and the extent to which the DCs generated in vitro resembled their in vivo counterparts required a more rigorous and global assessment. Here, we describe a cost-effective and robust in vitro differentiation system for the production of cDC1s and pDCs equivalent to their blood counterparts, from cord blood CD34 hematopoietic stem cells (HSCs) cultured on a stromal feeder layer with a combination of cytokines and growth factors.
树突状细胞 (DCs) 是宿主抵御病原体入侵的最重要的免疫细胞亚群之一,通过促进先天免疫和适应性免疫来发挥作用。大多数关于人类树突状细胞的研究都集中在体外从单核细胞 (MoDCs) 中获得的易于获取的树突状细胞上。然而,关于不同树突状细胞类型的作用仍有许多问题尚未得到解答。由于其稀有性和脆弱性,特别是 1 型传统树突状细胞 (cDC1s) 和浆细胞样树突状细胞 (pDCs),对它们在人类免疫中的作用的研究受到了阻碍。从造血祖细胞体外分化成为产生不同 DC 类型的常用方法,但这些方案的效率和可重复性需要提高,并且体外生成的 DC 在多大程度上类似于其体内对应物需要更严格和全面的评估。在这里,我们描述了一种经济高效且稳健的体外分化系统,可从脐血 CD34 造血干细胞 (HSCs) 中产生与血液对应物相当的 cDC1s 和 pDCs,该系统在基质饲养层上培养,并用细胞因子和生长因子组合。